Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2022

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Breast Cancer StageInsulin ResistanceRacial Bias
Interventions
DRUG

Metformin Extended Release Oral Tablet

initial dose of metformin of 750 mg Q.D. (with dinner) for 3-4 weeks. They then will be increased to the final dose of 750 mg BID (breakfast and dinner) until the end of the study.

Trial Locations (1)

70815

Woman's Hospital, Baton Rouge

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Our Lady of the Lake Hospital

OTHER

collaborator

American Cancer Society, Inc.

OTHER

collaborator

Pfizer

INDUSTRY

lead

Woman's

OTHER

NCT04741204 - Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer | Biotech Hunter | Biotech Hunter